Guo Yongjing, Pakneshan Pouya, Gladu Julienne, Slack Andrew, Szyf Moshe, Rabbani Shafaat A
Departments of Medicine and Pharmacology, McGill University Health Center, Montreal, Quebec H3A 1A1, Canada.
J Biol Chem. 2002 Nov 1;277(44):41571-9. doi: 10.1074/jbc.M201864200. Epub 2002 Aug 26.
Urokinase-type plasminogen activator (uPA) is a member of the serine protease family and can break down various components of the extracellular matrix to promote growth, invasion, and metastasis of several malignancies including breast cancer. In the current study we examined the role that the DNA methylation machinery might be playing in regulating differential uPA gene expression in breast cancer cell lines. uPA mRNA is expressed in the highly invasive, hormone-insensitive human breast cancer cell line MDA-MB-231 but not in hormone-responsive cell line MCF-7. Using methylation-sensitive PCR, we show that 90% of CpG dinucleotides in the uPA promoter are methylated in MCF-7 cells, whereas fully demethylated CpGs were detected in MDA-MB-231 cells. uPA promoter activity, which is directly regulated by the Ets-1 transcription factor, is inhibited by methylation as determined by uPA promoter-luciferase reporter assays. We then tested whether the state of expression and methylation of the uPA promoter correlates with the global level of DNA methyltransferase and demethylase activities in these cell lines. We show that maintenance DNA methyltransferase activity is significantly higher in MCF-7 cells than in MDA-MB-231 cells, whereas demethylase activity is higher in MDA-MB-231 cells. We suggest that the combination of increased DNA methyltransferase activity with reduced demethylase activity contributes to the methylation and silencing of uPA expression in MCF-7 cells. The converse is true in MDA-MB-231 cells, which represents a late stage highly invasive breast cancer. The histone deacetylase inhibitor, Trichostatin A, induces the expression of the uPA gene in MDA-MB-231 cells but not in MCF-7 cells. This supports the hypothesis that DNA methylation is the dominant mechanism involved in the silencing of uPA gene expression. Taken together, these results provide insight into the mechanism regulating the transcription of the uPA gene in the complex multistep process of breast cancer progression.
尿激酶型纤溶酶原激活剂(uPA)是丝氨酸蛋白酶家族的一员,可分解细胞外基质的各种成分,促进包括乳腺癌在内的多种恶性肿瘤的生长、侵袭和转移。在本研究中,我们研究了DNA甲基化机制在调节乳腺癌细胞系中uPA基因差异表达方面可能发挥的作用。uPA mRNA在高侵袭性、激素不敏感的人乳腺癌细胞系MDA-MB-231中表达,但在激素反应性细胞系MCF-7中不表达。使用甲基化敏感PCR,我们发现uPA启动子中90%的CpG二核苷酸在MCF-7细胞中甲基化,而在MDA-MB-231细胞中检测到完全去甲基化的CpG。如uPA启动子-荧光素酶报告基因检测所确定的,由Ets-1转录因子直接调节的uPA启动子活性受到甲基化的抑制。然后,我们测试了uPA启动子的表达和甲基化状态是否与这些细胞系中DNA甲基转移酶和去甲基酶活性的整体水平相关。我们发现,维持性DNA甲基转移酶活性在MCF-7细胞中显著高于MDA-MB-231细胞,而去甲基酶活性在MDA-MB-231细胞中更高。我们认为,DNA甲基转移酶活性增加与去甲基酶活性降低相结合,导致了MCF-7细胞中uPA表达的甲基化和沉默。在代表晚期高侵袭性乳腺癌的MDA-MB-231细胞中情况则相反。组蛋白去乙酰化酶抑制剂曲古抑菌素A可诱导MDA-MB-231细胞中uPA基因的表达,但不能诱导MCF-7细胞中uPA基因的表达。这支持了DNA甲基化是参与uPA基因表达沉默的主要机制这一假设。综上所述,这些结果为乳腺癌进展复杂多步骤过程中uPA基因转录调控机制提供了见解。